This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

March 23, 2026

Company name: Modalis Therapeutics Corporation
Stock exchange listing: Tokyo Stock Exchange
Code number: 4883
URL: https://www.modalistx.com/en/
Representative: Haruhiko Morita

Modalis Therapeutics to Present Latest Preclinical Data and Clinical Trial Plans for MDL-101 at the 2026 LAMA2 Conference

23-March-2026 TOKYO & Waltham, Mass – Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases utilizing its proprietary CRISPR-GNDM® epigenome editing technology, announced that it has been invited give an oral presentation at the 2026 LAMA2 Conference (March 27-29, 2026, Istanbul, Türkiye).

At the conference, Dr. Simon Moore, Director of Translational Research at Modalis, will present the advantages of the company's proprietary epigenetic editing technology (CRISPR-GNDM®) and the latest research results for MDL-101. The presentation will highlight the following key points:

- *Demonstration of significant efficacy in disease model mice*
- *Safety and target gene expression in Non-Human Primate (NHP) studies*
- *Clinical Phase 1/2 trial preparation and study design*

Presentation Details:

Title: Clinical Evaluation of LAMA1 Upregulation: Translating Decades of Research to Meaningful Outcomes for LAMA2-RD Patients

Session: Accelerating on the bumpy road to therapy

Date & Time: Sunday, March 29, 2026, 12:00-12:20 PM (Local Time)
Conference Website: Sunday Program — Lama-2 Conference

About the 2026 LAMA2 Conference

The LAMA2 Conference is an international platform dedicated to establishing treatments for LAMA2-related muscular dystrophy (LAMA2-RD), a rare genetic disorder. It brings together researchers, clinicians, patient organizations, and families from around the world. The conference aims not only to share the latest research findings but also to accelerate the development of effective care and treatments through dialogue between experts and the patient community. The third edition of this meeting will be held in Istanbul, Türkiye, under the theme "Getting Closer to a Treatment for LAMA2 RD."

About Modalis:

Modalis Therapeutics develops precision genetic medicines using epigenome editing technology. Modalis is pursuing therapies for orphan genetic diseases using its proprietary CRISPR-GNDM® technology which enables the gene/locus-specific modulation of gene expression or epigenetic editing without the need for DNA cleavage or altering DNA sequence. Headquartered in Tokyo with laboratories and facilities in Waltham Massachusetts, the company is listed on Tokyo Stock Exchange's Growth market. For additional information, visit www.modalistx.com.

For media contacts
Modalis Therapeutics
Sawako Nakamura
media@modalistx.com